Latest Ratios: P/E Ratio N/A · EV/EBITDA 20.0x · ROE -8.9%. (2019–2025 historical series)
Price-based multiples — how expensive the stock is relative to earnings, sales, book value, and cash flow
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 |
|---|---|---|---|---|---|---|---|---|
| Market Cap | $640M | — | — | — | — | — | — | — |
| Enterprise Value | $1.6B | — | — | — | — | — | — | — |
| P/E Ratio → | — | — | — | — | — | — | — | — |
| P/S Ratio | 1.87 | — | — | — | — | — | — | — |
| P/B Ratio | — | — | — | — | — | — | — | — |
| P/FCF | — | — | — | — | — | — | — | — |
| P/OCF | 92.08 | — | — | — | — | — | — | — |
P/E links to full P/E history page with 30-year chart
Enterprise-value multiples — capital-structure-neutral measures of total business value
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 |
|---|---|---|---|---|---|---|---|---|
| EV / Revenue | — | — | — | — | — | — | — | — |
| EV / EBITDA | 19.96 | — | — | — | — | — | — | — |
| EV / EBIT | 493.23 | — | — | — | — | — | — | — |
| EV / FCF | — | — | — | — | — | — | — | — |
Margins and return-on-capital ratios measuring operating efficiency
Full margin charts and quarterly trend are on the Earnings History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 |
|---|---|---|---|---|---|---|---|---|
| Gross Margin | 36.0% | 36.0% | 37.5% | 37.0% | 36.4% | 37.5% | 36.2% | 37.5% |
| Operating Margin | 1.0% | 1.0% | -34.9% | -1.4% | -9.4% | -11.4% | -5.2% | -8.5% |
| Net Profit Margin | -16.8% | -16.8% | -53.6% | -20.9% | -23.7% | -25.9% | -19.9% | -23.4% |
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 |
|---|---|---|---|---|---|---|---|---|
| ROE | -8.9% | -8.9% | -23.9% | -7.6% | -7.8% | -8.5% | -7.3% | -7.9% |
| ROA | -3.2% | -3.2% | -9.3% | -3.3% | -3.6% | -3.8% | -3.3% | -3.8% |
| ROIC | 0.1% | 0.1% | -4.8% | -0.2% | -1.1% | -1.3% | -0.7% | -1.1% |
| ROCE | 0.3% | 0.3% | -7.7% | -0.3% | -1.9% | -2.3% | -1.2% | -1.9% |
Solvency and debt-coverage ratios — lower is generally safer
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 |
|---|---|---|---|---|---|---|---|---|
| Debt / Equity | 1.73 | 1.73 | 1.67 | 1.31 | 1.12 | 1.05 | 1.28 | 1.03 |
| Debt / EBITDA | 12.82 | 12.82 | — | 15.25 | 22.39 | 25.88 | 20.07 | 23.21 |
| Net Debt / Equity | — | 1.63 | 1.63 | 1.26 | 1.06 | 0.99 | 1.20 | 0.95 |
| Net Debt / EBITDA | 12.11 | 12.11 | — | 14.65 | 21.31 | 24.46 | 18.89 | 21.26 |
| Debt / FCF | — | — | — | — | 3521.29 | 52.24 | 57.95 | 34.12 |
| Interest Coverage | 0.06 | 0.06 | -1.74 | -0.09 | -0.53 | -0.78 | -0.39 | -0.57 |
Short-term solvency ratios and asset-utilisation metrics
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 |
|---|---|---|---|---|---|---|---|---|
| Current Ratio | 0.24 | 0.24 | 0.21 | 0.28 | 0.17 | 0.20 | 0.16 | 0.31 |
| Quick Ratio | 0.24 | 0.24 | 0.21 | 0.28 | 0.17 | 0.20 | 0.16 | 0.31 |
| Cash Ratio | 0.10 | 0.10 | 0.05 | 0.11 | 0.09 | 0.11 | 0.10 | 0.14 |
| Asset Turnover | — | 0.20 | 0.18 | 0.16 | 0.15 | 0.15 | 0.17 | 0.16 |
| Inventory Turnover | — | — | — | — | — | — | — | — |
| Days Sales Outstanding | — | — | — | — | — | — | — | — |
Earnings, FCF, buyback, and dividend yields — total returns to shareholders
Full dividend history and growth charts are on the Dividend History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 |
|---|---|---|---|---|---|---|---|---|
| Dividend Yield | — | — | — | — | — | — | — | — |
| Payout Ratio | — | — | — | — | — | — | — | — |
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 |
|---|---|---|---|---|---|---|---|---|
| Earnings Yield | — | — | — | — | — | — | — | — |
| FCF Yield | — | — | — | — | — | — | — | — |
| Buyback Yield | 0.8% | — | — | — | — | — | — | — |
| Total Shareholder Yield | 0.8% | — | — | — | — | — | — | — |
| Shares Outstanding | — | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
Persistent Negative Net Income
According to quarterly financial disclosures, NHPBP's NOI margin has fluctuated between 33.4% and 38.7%, reflecting the high-cost nature of its SHOP segment and suggesting that the company struggles to achieve the scale necessary to offset rising labor and operational expenses across its healthcare facility portfolio.
The narrow NOI margin indicates that the company is highly sensitive to inflationary pressures within its operating portfolio. This lack of margin expansion suggests that organic growth is currently insufficient to cover the fixed costs associated with its medical office and senior housing assets.
Based on reported figures, the company's debt-to-equity ratio has trended upward to 1.76 as of 2026Q1, which, when viewed alongside an interest coverage ratio of 0.71, indicates a precarious balance sheet that may struggle to service existing debt obligations without further capital infusions or asset sales.
The deteriorating interest coverage ratio suggests that the company is failing to generate sufficient property-level income to comfortably meet its debt service requirements. Investors should monitor whether this leverage profile necessitates a restructuring of the capital stack to avoid further impairment of equity value.
As reported in recent financial statements, the FFO payout ratio has exhibited extreme volatility, reaching as high as 93.4% in 2024Q4, which highlights the significant risk to dividend sustainability given the company's inconsistent ability to generate positive FFO on a per-share basis.
The erratic nature of the payout ratio suggests that distributions are not supported by stable, recurring cash flows. This inconsistency warrants caution, as the company appears to be prioritizing payouts despite a lack of underlying earnings growth.
Investors frequently misapply the standard P/E ratio to NHPBP, which obscures the company's true economic performance by failing to account for the heavy non-cash depreciation charges inherent in healthcare real estate and the specific cash-flow requirements of the SHOP operating model.
Because depreciation is a non-cash expense that significantly reduces GAAP net income, the P/E ratio provides a distorted view of the company's valuation. Analysts should instead utilize P/FFO or P/AFFO to better capture the actual cash-generating capacity of the underlying real estate assets.
Includes 30+ ratios · 7 years · Updated daily
DCF models, multiple analysis, and analyst estimates.
10-year return with dividends reinvested.
See how regular investing compounds over time.
Compare growth, multiples, and margins vs sector.
Quick answers to the most common questions about buying NHPBP stock.
National Healthcare Properties, Inc.'s current EV/EBITDA is 20.0x. This enterprise value multiple compares the company's total value (equity + debt - cash) to its EBITDA.
National Healthcare Properties, Inc.'s return on equity (ROE) is -8.9%. The historical average is -10.3%.
Based on historical data, National Healthcare Properties, Inc. is trading at valuation metrics that vary. Compare with industry peers and growth rates for a complete picture.
National Healthcare Properties, Inc. has 36.0% gross margin and 1.0% operating margin.
National Healthcare Properties, Inc.'s Debt/EBITDA ratio is 12.8x, indicating high leverage. A ratio above 4x may signal elevated financial risk.